Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin for renoprotective effects in contrast-induced nephropathy prevention
TCTR20180816001Phase 3Not yet recruiting
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atorvastatin in contrast-induced nephropathy (CIN), sponsored by Ratchadaphiseksomphot Endowment Fund. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
atorvastatin
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on TCTR20180816001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20180816001.